<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210511051268N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-05-13</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of acetaminophen on propofol injection pain</public_title>
      <acronym></acronym>
      <scientific_title>The effect of premedication with oral acetaminophen on the prevention of localized pain from intravenous injection of propofol as induction agent in patients under general anesthesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>150</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56227</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Restricted randomization is done using permuted block randomization method, with six blocks. Randomization was performed using the website www.randomization.com. The method of concealment is to use opaque envelopes sealed in random sequence, Blinding description: Both the patient and an independent evaluator (in charge of anesthesia) and the researcher and data analyzer and the outcome evaluator are not aware of the type of oral medication. Placebo and paracetamol are the same in shape, size, color and weight.</study_design>
      <phase>3</phase>
      <hc_freetext>Local Pain due to intravenous injection of propofol.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: P500 group (patients with 500 mg of oral paracetamol) will receive medication 1 hour before transfer to the operating room. Each patient receives 1 placebo tablet and 1 paracetamol 500 mg tablet. (Because in the other intervention group, patients take 2 acetaminophen pills, so here they take one medicine pill and one placebo pill) None of them will receive any other analgesic or sedative. Aria 500 mg acetaminophen tablet is a product of Aria Pharmaceutical Company. Immediately after injecting a quarter of the propofol induction dose, the patient's local pain at the injection site is assessed by the VNRS numerical criterion and the patient scores from 0 to 10. Intervention 2: Control group: The placebo group receives the drug 1 hour before transfer to the operating room. Each patient receives 2 placebo tablets. (Because in one intervention group, patients take 2 acetaminophen pills, so here they take two placebo pills). None of them will receive any other analgesic or sedative. Immediately after injecting a quarter of the propofol induction dose, the patient's local pain at the injection site is assessed by the VNRS numerical criterion and the patient scores from 0 to 10. Intervention 3: Intervention group: Intervention group: P1000 group (patients with 1000 mg of oral paracetamol) receive medication 1 hour before transfer to the operating room. Each patient receives 2 tablets of 500 mg paracetamol. None of them will receive any other analgesic or sedative. Aria 500 mg acetaminophen tablet is a product of Aria Pharmaceutical Company. Immediately after injecting a quarter of the propofol induction dose, the patient's local pain at the injection site is assessed by the VNRS numerical criterion and the patient scores from 0 to 10.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after unidentified individuals

When:
Access period starts 6 months after the results are published

To whom:
Access is free for everyone

Conditions:
Access is free for everyone

Where to obtain:
Person in charge of the project / Seyed Mohsen Mousavi
sm.mousavi.md.anesthesiology@gmail.com

How to obtain:
Immediately after contacting the project manager

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyed Mohsen Mousavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran / Shahrak-e-Gharb / Dadman Blvd. / Sepehr St. / No. 117 / Unit 6</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1468734117</zip>
        <telephone>+98 21 8836 3149</telephone>
        <email>sm.mousavi.md.anesthesiology@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Mohsen Mousavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran / Shahrak-e-Gharb / Dadman Blvd. / Sepehr St. / No. 117 / Unit 6</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1468734117</zip>
        <telephone>+98 21 8836 3149</telephone>
        <email>sm.mousavi.md.anesthesiology@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All patients for whom propofol is used as an induction of anesthesia</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Weight less than 50 kg
Chronic pain in any area of ​​the body
High blood pressure
Cardiovascular disease
Cerebrovascular disease
Difficulty communicating (even if there is a marked drop in level of consciousness with the initial injection dose)
Cirrhosis
Abnormal liver function test results (AST and ALT more than twice normal)
Kidney failure or creatinine clearance greater than 1.2
Allergy to acetaminophen
Allergy to propofol
Patients in whom propofol is not used to induce anesthesia
Those who do not have a venous catheter in the back of the hand
Those whose catheter size is not 20G
those for whom we have to use rapid sequence induction for their anesthesia</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M79.643</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pain in unspecified hand</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: P500 group (patients with 500 mg of oral paracetamol) will receive medication 1 hour before transfer to the operating room. Each patient receives 1 placebo tablet and 1 paracetamol 500 mg tablet. (Because in the other intervention group, patients take 2 acetaminophen pills, so here they take one medicine pill and one placebo pill) None of them will receive any other analgesic or sedative. Aria 500 mg acetaminophen tablet is a product of Aria Pharmaceutical Company. Immediately after injecting a quarter of the propofol induction dose, the patient's local pain at the injection site is assessed by the VNRS numerical criterion and the patient scores from 0 to 10.</i_keyword>
      <i_keyword>Control group: The placebo group receives the drug 1 hour before transfer to the operating room. Each patient receives 2 placebo tablets. (Because in one intervention group, patients take 2 acetaminophen pills, so here they take two placebo pills). None of them will receive any other analgesic or sedative. Immediately after injecting a quarter of the propofol induction dose, the patient's local pain at the injection site is assessed by the VNRS numerical criterion and the patient scores from 0 to 10.</i_keyword>
      <i_keyword>Intervention group: Intervention group: P1000 group (patients with 1000 mg of oral paracetamol) receive medication 1 hour before transfer to the operating room. Each patient receives 2 tablets of 500 mg paracetamol. None of them will receive any other analgesic or sedative. Aria 500 mg acetaminophen tablet is a product of Aria Pharmaceutical Company. Immediately after injecting a quarter of the propofol induction dose, the patient's local pain at the injection site is assessed by the VNRS numerical criterion and the patient scores from 0 to 10.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>11-point verbal numerical rating score (VNRS) for pain caused by propofol injection. Timepoint: Measuring the amount of pain right after injecting a quarter of the induction dose. Method of measurement: 11-Point Verbal Numerical Ranking (VNRS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-09-02</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Enghelab St., Ghods St., Poursina St. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
